StockNews.com Begins Coverage on Cara Therapeutics (NASDAQ:CARA)

StockNews.com started coverage on shares of Cara Therapeutics (NASDAQ:CARA) in a research report sent to investors on Monday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Cara Therapeutics Stock Up 8.2 %

Shares of NASDAQ:CARA opened at $0.46 on Monday. The stock has a market cap of $25.09 million, a PE ratio of -0.26 and a beta of 0.64. Cara Therapeutics has a 12-month low of $0.23 and a 12-month high of $1.15. The business has a 50 day moving average of $0.30 and a 200-day moving average of $0.32.

Institutional Trading of Cara Therapeutics

A number of institutional investors have recently bought and sold shares of CARA. XTX Topco Ltd bought a new stake in shares of Cara Therapeutics in the third quarter valued at approximately $29,000. Disciplined Growth Investors Inc. MN raised its holdings in Cara Therapeutics by 6.6% in the 2nd quarter. Disciplined Growth Investors Inc. MN now owns 1,935,718 shares of the biopharmaceutical company’s stock valued at $499,000 after acquiring an additional 120,660 shares in the last quarter. Finally, FMR LLC lifted its position in shares of Cara Therapeutics by 18.5% during the 3rd quarter. FMR LLC now owns 210,312 shares of the biopharmaceutical company’s stock valued at $65,000 after acquiring an additional 32,789 shares during the period. Institutional investors own 44.66% of the company’s stock.

Cara Therapeutics Company Profile

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.